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Transforming growth factor beta
Development
CancerEpithelial–mesenchymal transition (EMT) and mesenchymal–epithelial transition (MET) highlight crucial steps
during embryogenesis and tumorigenesis. Induction of dramatic changes in gene expression and cell features is
reflected bymodulation of Cdh1 (E-cadherin) expression.We show that Cdh1 activity duringMET is governed by
two enhancers at +7.8 kb and at +11.5 kb within intron 2 that are activated by binding of Grhl3 and Hnf4α,
respectively. Recruitment of Grhl3 and Hnf4α to the enhancers is crucial for activating Cdh1 and accomplishing
MET in non-tumorigenic mouse mammary gland cells (NMuMG). Moreover, the two enhancers cooperate via
Grhl3 and Hnf4α binding, induction of DNA-looping and clustering at the promoter to orchestrate E-cadherin
re-expression. Our results provide novel insights into the cellular mechanisms whereby cells respond to MET
signals and re-establish an epithelial phenotype by enhancer cooperativity. A general importance of our findings
including MET-mediated colonization of metastasizing tumor cells is suggested.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Many key steps during embryogenesis result in the formation of new
cell types with unique features. They become morphologically visible
when individual cells or tissues are generated by cell delamination
during a process called epithelial–mesenchymal transition (EMT) or by
cell clustering and re-epithelialization during mesenchymal–epithelial
transition (MET). EMT is required for mesoderm formation, neural crest
cell delamination, fibrosis and wound healing, but is also aberrantly
activated during tumorigenesis when cancer cells start to disseminate,
invade and formmetastases [1–3]. Common to all types of EMT are cyto-
skeletal rearrangements resulting in loss of cell polarity and adherent
morphology combinedwith increasedmigration. Gene expression signa-
tures are changing dramatically with amajor impact on the repertoire of
cell adhesion molecules, especially of Ca2+-dependent adhesion
molecules, the cadherins [4]. Strikingly, changes in cellular char-
acteristics during a bona fide EMT are to a large extent dependent+49 9131 85 29341.
r).on the downregulation of E-cadherin (E-cad) and the activation
of N-cadherin (N-cad), regulated by the EMT program [1].
MET is considered as the reverse process of EMT and also origi-
nates from embryogenesis [5,6]. Here, mesenchymal cells acquire
epithelial characteristics including loss of N-cad and activation of
E-cad expression [1–3]. In addition to orchestrating morphogenetic
events during embryogenesis the process of MET is utilized by dissem-
inating tumor cells and is required for colonization and formation of
metastases at distant sites [1,2,7]. In vitro MET is necessary for somatic
cell reprogramming. During the generation of induced pluripotent
stem (iPS) cells, MET precedes the activation of the endogenous loci
of transcription factors of the core pluripotency network [8]. This is
in part established by the activation of E-cad expression via direct
binding of exogenous Klf4 to specific sites at the promoter [9].
Interestingly, E-cad supports the initiation of MET and increases
reprogramming efficiency [10]. In contrast, E-cad depletion results in
loss of pluripotency and decreases the potential for reprogramming
[11]. All these findings depict EMT, MET and a tightly regulated ex-
pression of cadherins as crucial during many different processes in
development and disease.
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include changes in the cadherin repertoire. An essential step of EMT is
the downregulation of E-cad whereas its expression is rapidly restored
during MET. Many different extracellular signals are known to trigger
EMT leading to activation of intracellular EMT-inducers like Snail,
Slug, Twist, Zeb1, Zeb2 and others [1,2]. In agreement with a re-
quired fast downregulation of E-cad, all of these transcription factors
are in fact repressors of E-cad expression and they all bind to several
evolutionary conserved E-boxes present in the proximal promoter
[12–18]. However, the immediate activation of the Cdh1 locus during
MET can only in part be explained by the downregulation and release
of these repressors. We found that the Cdh1 promoter alone, including
all known E-box elements, is insufficient to confer strict cell type
specificity. In contrast, intron 2 carries sufficient information for proper
E-cad expression [19,20]. In particular, we identified sequences in the
proximal 15 kb of the 45 kb spanning intron 2, that showed cell type
specific gene activation, mainly in the endoderm [20]. Moreover, an
endogenous Cdh1 allele lacking the entire intron 2 failed to activate
expression of a reporter, showing that intron 2 is essential for the initi-
ation and maintenance of E-cad expression during development [19].
Although intron 2 has emerged as an essential regulator of Cdh1 expres-
sion, very little is known about the molecular determinants controlling
the transcriptional activity of the locus. Besides Klf4, it has been shown
that Grainyhead-like 2 (Grhl2), a mammalian homolog of Drosophila
grainyhead, controls epithelial differentiation in several epithelia and at
uretic bud formation by regulating E-cad via binding to an element in
intron 2 [21].
Here, we sought to identify novel enhancers within intron 2 of Cdh1
and to discover the corresponding transcription factors that mediate
gene activation. We used non-tumorigenic mouse mammary gland
epithelial cells (NMuMG) that undergo a reversible EMT by transforming
growth factor β (TGFβ) treatment. We identified two potent enhancers
that cooperate in establishing prompt and robust E-cad expression
during the induction of MET. Furthermore, we provide evidence that
transcriptional activity from these enhancers is mediated by two novel
E-cad activators, Grhl3 and Hnf4α, which emerge as regulators of MET
in NMuMG cells.
2. Materials and methods
2.1. Cell culture and induction of EMT and MET
NMuMG; non-tumorigenic mouse mammary gland cell line,
Hepa1–6; mouse hepatoma cell line, CMT; mouse polyploid carcinoma
cell line andHEK-293; human embryonic kidney cell linewere obtained
from ATCC. Cells were maintained in DMEM (Gibco) and 10% fetal
bovine serum (FBS) at 37 °C, 10% CO2. NMuMG medium was supple-
mented with 10 μg/ml insulin (Sigma). EMT induction of NMuMG
cells was done by applying 5 ng/ml TGFβ3 (PeproTech) for 72 h. The re-
versible transition to the epithelial state (MET) was induced by TGFβ3
withdrawal, washing the plates twicewith PBS and incubation for addi-
tional 72 h in fresh medium.
2.2. Luciferase reporter assays
Reporter plasmids and expression vectors used here are available
in the Supplemental Experimental Procedures. Cells in 48-well
plates were transfected with plasmid DNAs using X-tremeGENE 9
transfection reagent (Roche). Transfection was carried out with
100 ng DNA containing 5 ng pRL-TK (Promega) to normalize for
transfection efficiency. We normalized to equal molarity of the plasmid
to use equal copies of reporter plasmid. Absolute DNA content was
equalized by addition of promoter-less plasmid DNA. In experiments
with TGFβ3, the drug was added at the time point of transfection.
Cells recovering from TGFβ3 treatment (PT) were transfected upon
TGFβ3 withdrawal and measured after 3 days of recovery. 20 ng ofGrhl3, Grhl2, Grhl1 and Hnf4a expression plasmid or empty vector
(mock) were transfected. Luciferase reporter activity was measured
using Dual-Glo Luciferase Assay (Promega) in a Centro LB 960
luminometer (Berthold Technologies). Firefly luciferase reporter values
were normalized to those of the Renilla luciferase control. Fold induc-
tion was calculated relative to the values of the empty vector or vehicle
control samples.
2.3. Generation of transgenic embryos
Animal husbandry and all experiments were performed according
to the German Animal Welfare guidelines and approved by the local
authorities. The reporter construct TG3 (Wt) or the one with mutated
Grhl3 binding site 7.8b (Mut) were injected into oocytes as described
[20].
2.4. Chromosome conformation capture (3C)
The protocol for 3C was described previously [22]. In brief, cells
were grown in the presence or absence of 5 ng/ml TGFβ3 and
allowed to recover after TGFβ3 withdrawal and cross-linked with
1% formaldehyde for 10 min at room temperature. After lysis on ice
for 10 min in lysis buffer (10 mM Tris–HCl, pH 7.5; 10 mM NaCl;
5 mM MgCl2; 0.1 mM EGTA; 1× complete protease inhibitor), nuclei
were incubated with TaqI for 90 min at 37 °C. Purified DNA was used
together with BAC RP23-262 N14 DNA containing the murine Cdh1
locus for qPCR analysis. Primers used are presented in Supplementary
Table S4.
2.5. Chromatin immunoprecipitation (ChIP)
ChIP was performed as reported previously [23] with minor modifi-
cations as depicted in the Supplemental Experimental Procedures using
Grhl3 (S-19, Santa Cruz), Hnf4α (H-171, Santa Cruz), p300 (C-20, Santa
Cruz), H3K9Ac (ab4441, Abcam), H3K4me1 (ab8895, Abcam) and a
rabbit control IgG (sc-2027, Santa Cruz) antibodies.
2.6. Co-immunoprecipitation and immunoblotting
Immunoprecipitation was done as described in detail in the Supple-
mental Experimental Procedures using 1 mg nuclear extracts and 25 μl
of anti-HA affinity matrix (Roche) or 4 μg of anti-FLAG antibody (M2,
Sigma) coupled to Protein-G Dynabeads.
2.7. Statistical analysis
Statistical significance was determined by performing the Student's
t-test using the normalized values of each test sample compared to
the normalized value of the control, using a 95% confidence interval;
p-values less than 0.05 were considered significant. Data are pre-
sented as the mean of at least three independent experiments,
done in triplicates. ChIP and 3C were carried out three times, qPCR
was performed in triplicates. Error bars represent standard error of
the mean.
3. Results
3.1. Intron 2 of Cdh1 harbors conserved and potent enhancers
We reported previously that intron 2 of Cdh1 is essential for proper
E-cad expression [19,20]. In order to analyze this large DNA sequence
(N40 kb) for putative enhancers we focused on evolutionary conserved
sequences. We rationalized that a conserved expression pattern is
reflected by a conserved regulatory mechanism utilizing the same en-
hancers conserved in highly similar genomic regions among different
species [24]. To identify such putative enhancers, we used the mVista
Fig. 1. Identification of functional conserved sequenceswithin Cdh1 intron 2. (A) Amap of
the conserved clusters is shown in relation to the Cdh1 gene, location and size of clusters
are in scale. Cl.1–Cl.20 indicate individual clusters and refer to the Luciferase constructs
below (Supplementary Table S1). (B) Luciferase assay of constructs harboring conserved
clusters in E-cad expressing and E-cad negative cell lines. Relative luciferase is calculated
as fold induction relative to the empty vector pGL4.23. (C) Reporter gene activity of select-
ed clusters in NMuMG cells in response to three days of vehicle and TGFβ3 treatment as
well as after three days of TGFβ3 withdrawal (post-treatment, PT). (D) qRT-PCR analysis
of endogenous E-cad mRNA in response to TGFβ3. *, p b 0.05; **, p b 0.01; ***,p b 0.001.
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of the Cdh1 locus, and compared the genome of mouse to those of
human, rhesus, dog, and horse (Supplementary Fig. S1A, Supplementary
Table S1). We identified several sequences with more than 70% conser-
vation in a 150 bp window consistent with our previous analysis [19].
These conserved clusters were distributed over the entire intron 2
(Fig. 1A). Individual clusters were cloned into a luciferase reporter
vector, upstream of a minimal promoter (Supplementary Fig. S1B) and
their enhancing potentialwas analyzed bymeasuring luciferase activity.
We used two E-cad expressing (non-tumorigenic mammary gland and
rectal polyploid carcinoma cells, NMuMG and CMT, respectively) and
two E-cad negative cell lines (immortalized embryonic kidney and
hepatoma cells, HEK-293 andHepa1–6). To identify themost important
sequences, the clusters were sorted out with respect to importance for
E-cad regulation by two criteria. First we selected conserved sequences
with stronger activity in cells expressing E-cad compared to those
which are E-cad negative (Fig. 1B). The analysis showed that 8 out of
the 20 clusters had stronger activity in the E-cad+ cell line NMuMG
when compared to the E-cad− cell lines (Fig. 1B, Supplementary
Fig. S1B). None of the clusters showed strong activity in CMT cells, indi-
cating a more complex mode of regulation exceeding the limitation of
this technique (Fig. 1B, Supplementary Fig. S1B). As a second criterion
8 clusters with a higher activity in E-cad + cell lines were tested for
changes in reporter activity during EMT in response to TGFβ3 treatment
and during MET after TGFβ3 withdrawal (post-treatment, PT) in
NMuMG cells (Fig. 1C, Supplementary Fig. S1C). In total three conserved
sequences were found to be responsive to TGFβ3, but the reporteractivity of only two (Cl.3 and Cl.5) recapitulated the expression of
E-cad in response to TGFβ3, whereas Cl.2 showed inverse correlation
(Fig. 1C and D).3.2. Grhl3 but neither Grhl1 nor Grhl2 activates Cdh1 via an intronic
enhancer in Cl.3 in NMuMG cells
We used the MatInspector tool from the Genomatix Suite [26] to
screen Cl.3 and Cl.5 for transcription factor binding sites. We identified
a recognition motif in Cl.3 for grainyhead-like transcription factors,
proteins known to be required for pattern specification and tissue
development in several species including Drosophila [27–30]. In mice
it has been recently shown that Grhl2 is controlling E-cad expression
duringMET of uretic bud formation by binding to two highly conserved
Grhl motifs in tandem within intron 2 located at 7.8 kb (7.8a and 7.8b)
relative to the transcription start site (TSS) [21] (Supplementary
Fig. S2A). We searched for presence of Grhl binding sites in intron 2
and restricted the analysis to the proximal 11 kb, which we previously
identified as being sufficient to faithfully recapitulate endodermal
E-cad expression in transgenic reporter mice [20]. In total we identified
17 putative Grhl binding sites,five of which are locatedwithin the 11 kb
fragment (Fig. 2A, Supplementary Table S2). We tested whether the
recognition motifs were also functional Grhl2 binding sites and utilized
for Cdh1 regulation in NMuMG cells by luciferase reporter assays. The
architecture of the locus was maintained in the reporter constructs by
cloning the luciferase reporter between the promoter (nucleotides
from −1490 to +1) and the entire region between +0.1 kb and
+11 kb of the Cdh1 gene (Cl.1–4) (Fig. 2A). To our surprise, we found
that Cl.1–4 was not activated by neither Grhl2 nor Grhl1. In contrast, ec-
topic Grhl3 expression increased reporter gene activity 4-fold (Fig. 2B,
Supplementary Fig. S2F).
We also created several deletion constructs for analysis of individual
binding sites that contained one or two of the four conserved clusters
from the analysis in Fig. 1. In addition to the original 11 kb fragment,
containing Cl.1–4 and sites 1.4, 2.4, 7.8a, 7.8b and 9.6, only deletion con-
structs containing Cl.3 were significantly activated by Grhl3 (Fig. 2B).
Including downstream sequences up to 16 kb containing Cl.1–5 and
sites 10.7, 12.7 and 13.7 did not significantly increase reporter gene
activity (Supplementary Fig. S2B and C). Furthermore, we introduced
point mutations in the Grhl3 binding sites at 7.8a, 7.8b and 9.6 (Supple-
mentary Fig. S2D), and found that the mutation at site 7.8b already re-
duced the basal activity, indicating that endogenous Grhl3 is no longer
able to bind and activate the construct. Moreover, this mutation
completely abolished the Grhl3-dependent upregulation (Fig. 2C) and
resulted in impaired regulation of the reporter during TGFβ3 treatment
(Fig. 2D). In contrast, mutating site 7.8a had only moderate effects and
the construct with a mutation at site 9.7 retained full activity in re-
sponse to Grhl3 (Fig. 2C, Supplementary Fig. S2C). This suggested a pos-
sible role for Grhl3 in regulating transcription from the enhancer at site
7.8b in response to TGFβ3.
In order to assess the functionality of this enhancer and the require-
ment for Grhl3-dependent regulation in vivo independent of MET
events, we used themouse transgenic lacZ-reporter TG3, corresponding
to Cl.1–4 [20]. We introduced a point mutation in the Grhl3 binding
site at 7.8b and analyzed the reporter expression in the developing
mouse embryo at E11.5. In agreement with our previous findings,
embryos injected with the wildtype reporter (Wt, n = 9/9 X-gal
positive embryos) were characterized by β-gal expression in the en-
doderm of the pharynx, esophagus, lung, stomach and pancreas,
reflecting an expression pattern similar to that of E-cad. To our surprise,
this expression was absent in embryos carrying the mutant construct
(Mut, n = 0/16 X-gal positive embryos), indicating an important role
for the Grhl3 motif in regulating the expression of E-cad in endodermal
epithelia of the developing mouse embryo (Fig. 2E, and Supplementary
Fig. S2E).
Fig. 2. Grhl3 activates a potent enhancer in Cl.3 of intron 2. (A) A schematic representation of the Cdh1 locus is given in the upper panel, with the vertical lines above the locus map
depicting the identified Grhl-binding sites between −1.5 and +16 kb. Below is a representation of the maps of the luciferase reporter vectors under the control of the Cdh1 promoter.
Shaded boxes represent conserved clusters included in the constructs. Numbers and vertical lines represent relative positions of Grhl binding motifs and dashed lines indicate excluded
sequences (Supplementary Table S2). (B) Luciferase assays inNMuMGcells showing the effect of Grhl1, Grhl2 orGrhl3 on the indicated reporter construct. (C) Luciferase assays inNMuMG
cells studying the Grhl3 function in response to point mutations in the Grhl-binding sites at 7.8a+ b and 9.6. (D) Analysis of the construct with themutated Grhl-binding site after TGFβ3
treatment and after withdrawal. Relative luciferase activity is calculated as fold induction relative to vector (B and C) or to vehicle (D; Supplementary Table S3). (E) Analysis of transgenic
embryos using a control lacZ-reporter construct similar to Cl.1–4 (Wt) and the corresponding one that harbors a mutation in the Grhl-binding site at +7.8 (Mut). Representativemidsag-
ittal sections of X-gal stained E11.5 embryos are shown with higher magnifications of the X-gal positive domains.
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When we investigated the presence of Grhl3 on the Cdh1 chromatin
in untreated NMuMG cells by ChIP as an indication of direct binding, we
could not detect significant enrichment of Grhl3 on any of the predicted
sites, including the functional site at 7.8b under steady state conditions
(Fig. 3A, vehicle). We then took advantage of the ability of these cells to
undergo TGFβ-dependent reversible EMT. TGFβ3 treatment for 72 h
induced EMT, indicated by downregulation of E-cad and upregulation
of Vimentin. Uponwithdrawal of TGFβ3 the cells undergoMET resulting
in re-expression of E-cad (Supplementary Fig. S3A and B). We investi-
gated a possible enrichment of Grhl3 on E-cad during MET after
TGFβ3 withdrawal. We found that Grhl3 was significantly enriched at
two of the Grhl3 sites (sites 2.4 and 7.8a + b) and also at the TSS 72 h
post-treatment (Fig. 3A, PT), but not in cells treatedwith vehicle control
or TGFβ3 (Fig. 3A).In an effort tomechanistically address the observed Grhl3-dependent
regulation of E-cad during MET, we investigated the enhancer–promoter
interaction. We designed 3C experiments and compared the relative
crosslinking frequencies in NMuMG cells in response to EMT–MET
stimuli. Changes in chromosome conformation (DNA looping) can be
depictedbymeasuring crosslinking frequencies of intermolecular ligation
products, which represent enhancer–promoter interactions [22]. We
used several primers located within intron 2 (Fig. 3B, Supplementary
Table S4) and performed the qPCR analysis using a common anchoring
primer near the promoter (RT1). We detected elevated crosslinking fre-
quencies with primers corresponding to the location of the enhancers
at 2.4 and 7.8a + b (FI2 and FG2; fragments 3 and 6 respectively) com-
pared to primers located elsewhere between +1 and +16 kb (Fig. 3B).
Importantly, the crosslinking frequencies of cells undergoing MET were
significantly higher than of those treated with TGFβ3 or vehicle, suggest-
ing that such enhancers were in close proximity to the promoter. These
results are supporting the ChIP experiments, suggesting that in the initial
Fig. 3. Grhl3 is enriched at the intronic enhancers during mesenchymal–epithelial transi-
tion (MET). (A) ChIPwith anti-Grhl3 antibodies in NMuMG cells undergoing EMT-MET in
response to TGFβ3 treatment. Analysis of Grhl-binding sites in comparison to a non-relat-
ed control sequence (−17 kb) shows specific enrichment at the Cl.3 enhancer containing
binding site+7.8 and at a novel site at+2.4 aswell as at the transcriptional start site (TSS;
Supplementary Table S5). (B) Chromosome conformation capture (3C) experiment of the
Cdh1 locus in response to TGFβ3. The schematic representation of the Cdh1 locus indicat-
ing the location of the enhancers (vertical lines above) the location of TaqI restriction sites
(vertical lines below), and the location of the primers used (arrow heads represent
orientation). The capped lines below indicate the primer pair used to amplify each 3C
fragment (Supplementary Table S4 and S5).
Fig. 4. Grhl3 depletion results in E-cad downregulation and a failure of MET. (A) qPCR
analysis of mRNA of NMuMG cells recovering from TGFβ3 treatment after Grhl3 knock-
down using three different siRNAs and the effect on E-cad mRNA levels (Supplementary
Table S6). (B) Immunofluorescence labeling and phalloidin staining of NMuMG cells
visualizing the change in expression and intracellular distribution of E-cad, Vimentin
and Actin during TGFβ3 treatment and withdrawal. Actin distribution (Phal, green) and
detection of E-cad (red) and Vimentin (red) is shown. Nuclei are labeled with DAPI.
Scale bar, 50 μm.
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may lead to an interaction of the Grhl3–DNA enhancer complex with
the basal transcription machinery assembled at the promoter. Alterna-
tively, binding of a preassembled Grhl3/basal transcription machinery/
co-factor complex is stabilized by Grhl3–DNA binding at the enhancer.
Both scenarios are in line with a gradual increase in Cdh1 mRNA levels
after TGFβ3 withdrawal (Fig. 1D). No evidence for Grhl3 binding to the
putative site at 2.4 was found by luciferase reporter assays in NMuMG
cells (Supplementary Fig. S2C). A mutation at site 7.8b alone was suffi-
cient to abrogate Grhl3-dependent luciferase reporter activation and
also the lacZ-reporter activity in transgenic embryos. In contrast, 3C andChIP data revealed that this enhancer is utilized and recruits Grhl3
to the site at 2.4 in a context-dependent manner. Specifically, it is active
during MET after TGFβ3 withdrawal. Some of the primers used in this
experiment were in close proximity to the conserved sequence Cl.5
from Fig. 1 (primers FH2 and RH1; fragment 9). Although there was no
detectable interaction between this conserved sequence and the promot-
er in this context,wewere able to detect a significant interactionwith the
enhancer at 7.8a+b (primers RH1 and FG2; fragment 8), whichwas also
a TGFβ3 responsive interaction detectable during MET (Fig. 3B, PT), sug-
gesting a possible interplay between these two enhancers at 11.5 and
7.8a + b.
We then analyzed the effect of Grhl3 downregulation on E-cad ex-
pression in NMuMG cells using several Grhl3 siRNAs. We found that
two of the three analyzed siRNAs resulted in more than 80% downregu-
lation of Grhl3 (Fig. 4A). This reduction in Grhl3 expression resulted in a
significant decrease in E-cad expression levels only in cells recovering
from TGFβ3 treatment (Fig. 4A), but not in cells treatedwith the vehicle
(Supplementary Fig. S3C). We also noticed that with increasing
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more apparent (Fig. 4A, compare siGrhl3-1 and siGrhl3-2). To our
surprise, the siRNA mediated loss of Grhl3 expression after TGFβ3 with-
drawal blocked MET (Fig. 4B). This was evident by the absence of E-cad
expression, elevatedVimentin expression and the arrangement of cortical
actin in stress fibers, reminiscent of continuous TGFβ3-mediated EMT
(Fig. 4B, Supplementary Fig. S3D and E). A similar block of MET can also
beobserved in cells transfectedwith siRNAs targeting E-cadduring the re-
covery from TGFβ3 treatment (Supplementary Fig. S3E). This indicated
that Grhl3 function in this context is indispensable for proper MET. In
part this is accomplished by Grhl3 positively regulating the expression
of E-cad, which is essential for proper transition to the epithelial state
after TGFβ3 withdrawal.
3.4. Hnf4α specific regulation of E-cad via Cl.5 in a
TGFβ-dependent manner
Our analysis showed that the mode of action of the enhancer within
Cl.3 is mainly mediated by Grhl3 during MET of NMuMG cells andFig. 5. Cl.5 harbors a potent and conserved Hnf4α binding site. (A) Sequence alignment of the i
indicate identical bases. Introduced point mutations in the binding site are given. (B) Luciferase
mutated binding site for Hnf4α in Cl.5 with or without Hnf4α expression plasmids. (C) Mutat
changes in activity in response to TGFβ3. Relative luciferase activity is calculated as fold induct
with anti-Hnf4α (D and E) or anti-Grhl3 (F) antibodies inNMuMGcells in response to TGFβ3 (S
bound enhancers at 2.4 and 7.8 (E) and Grhl3 is bound to the 11.5 enhancer (F).during embryogenesis in the endoderm. Next, we investigated the con-
tribution of Cl.5 to Cdh1 gene regulation in mammary epithelial cells
before and after TGFβ3 treatment. We searched the sequences of Cl.5
for the presence of putative transcription factor binding sites using the
MatInspector tool of the Genomatix suite [26]. Among the several hits
obtained wewere particularly interested in a highly conserved recogni-
tion motif for the orphan nuclear receptor hepatocyte nuclear factor 4
alpha (Hnf4α) located at 11.5 relative to the TSS (Fig. 5A, Supplementa-
ry Fig. S1A). Hnf4α, which is faithfully coexpressedwith E-cad, was pre-
viously shown to regulate several adhesionmolecules (including E-cad)
during fetal liver organogenesis [31]. Using luciferase reporter assays,
we first tested whether Hnf4α could activate Cl.5 in NMuMG cells. We
found that indeed Hnf4α was able to exert a robust enhancing effect
on the E-cad Cl.5 reporter construct. Two different mutations in the pu-
tative Hnf4α binding site decreased the basal activity of this construct
and inhibited its Hnf4α-dependent activation (Fig. 5B). Furthermore,
we found that the two mutations in the Hnf4α consensus motif were
sufficient to abolish recovery of the reporter activity upon withdrawal
of TGFβ3 (Fig. 5C), suggesting that this recovery is Hnf4α dependent.dentified Hnf4α binding site in several species. The consensus is highlighted and asterisks
reporter assay in NMuMG cells transfected with reporter constructs containing the wt or
ions in the Hnf4α binding site significantly affects the basal activity of Cl.5 and abolishes
ion relative to empty vector control pGL4.23 (B) or to vehicle (C). (D–F) ChIP experiments
upplementary Table S5). Hnf4α is enriched at the 11.5 enhancer (D) aswell as at the Grhl3
737H. Alotaibi et al. / Biochimica et Biophysica Acta 1849 (2015) 731–742The remaining Hnf4α-dependent increase in activity of the mutant
reporter constructs was not significant.
Using ChIP experiments we detected significant enrichment of
Hnf4α on this novel enhancer in NMuMG cells in a TGFβ-dependent
fashion (Fig. 5D). In contrast to Grhl3 enrichment on the Cl.3 intronic
sites, Hnf4α recruitment to the chromatin was detectable already in
untreated NMuMG cells under steady state conditions, suggesting a dis-
tinct function for this enhancer. Hnf4α disappeared from Cl.5 during
TGFβ3-mediated EMT and Cdh1 downregulation and it was enriched
1.5 fold 72 h after TGFβ3 withdrawal (Fig. 5D). To our surprise, we
also detected significant enrichment of Hnf4α at both Grhl3 enhancers
at sites 2.4 and 7.8a + b (Fig. 5E, Supplementary Fig. S4C). A similar
enrichment of Grhl3 was identified at the Hnf4α binding site at 11.5
(Fig. 5F). This indicated a possible interaction between these two en-
hancers in agreement with the 3C results that showed looping of Cl.5
to the region of Cl.3.
3.5. Grhl3 and Hnf4α functionally interact at the intronic enhancers
The Hnf4α enrichment at the Grhl3 enhancers and the interaction
observedwith 3C experiments intrigued us to look for a potential genet-
ic or physical interaction between the two factors and between Cl.3 and
Cl.5. Firstwe performed luciferase reporter assays using Cl.3 and studied
the effect of overexpressing Hnf4α on Grhl3 function. We observed a
significant increase in reporter activity when Hnf4αwas introduced to-
gether with Grhl3 compared to the Grhl3-specific activation alone
(Fig. 6A). While Hnf4α alone did not increase the reporter activity, the
observed effect of Hnf4α over Grhl3 was specific, since no increase
was visible when we introduced Cebpα as control (data not shown).
Next, we used siRNAs to downregulate Hnf4α expression (Supple-
mentary Fig. S4A), and found that the absence of Hnf4α resulted in a
modest but significant decrease in the Grhl3-dependent activation of
the reporter, compared to the control (Fig. 6B). We wanted to deter-
mine if a similar effect could be observed on Cdh1 chromatin. For this
purpose, we first treated NMuMG cells with TGFβ3 for 72 h and at the
time of TGFβ3 withdrawal, cells were transfected with siRNAs targeting
Hnf4a. After 72 hpost-treatmentweperformedChIP usingGrhl3 specific
antibodies andmeasured the Grhl3 enrichment at the previously identi-
fied Grhl3 sites and at the promoter. As anticipated, loss of Hnf4α
expression dramatically reduced the Grhl3 enrichment at the Cdh1
intronic enhancers as well as at the promoter (TSS), although the latter
does not contain consensus sites for Hnf4α and Grhl3 (Fig. 6C, Supple-
mentary Fig. S4E). This was accompanied by a modest but significant
decrease in the levels of E-cad mRNA as measured by qPCR (Fig. 6D).
We hypothesized that the Hnf4α-dependent recruitment of Grhl3 to
intronic enhancers may be due to a physical interaction between the
two proteins and validated this by co-immunoprecipitation experi-
ments. We transfected HA-Hnf4α into NMuMG cells during MET after
TGFβ3 removal. Anti-Grhl3 immunoprecipitation revealed a complex
of Hnf4α and Grhl3 as indicated by the co-immunoprecipitation of
HA-Hnf4α (Supplementary Fig. S4B). Physical interaction was also con-
firmed in HEK-293 cells ectopically expressing tagged versions of the
two proteins. To abolish DNA-mediated indirect coupling of the two
transcription factorswe digestedDNAby benzonase treatment of cell ly-
sates. Immunoprecipitation of either HA-Hnf4α or flag-Grhl3 resulted in
specific co-precipitation of the corresponding binding partner (Fig. 6E).
p300 is a crucial co-factor of Hnf4α-mediated gene regulation and
found in the PolII-transcription initiation complex at many promoters
[32,33]. p300 was detected on both enhancers in control cells and at
the TSS with highest enrichment at the Grhl3 enhancer at 7.8a + b. Im-
portantly, these levels were diminished upon depletion of Hnf4α
(Fig. 6F), indicating that p300 recruitment was Hnf4α-dependent.
Moreover, we addressed the effect of Hnf4α depletion on the architec-
ture of Cdh1 chromatin by looking at an active histonemark (acetylation
at Lys9 of H3, H3K9Ac, Fig. 6G) and one that is associated with en-
hancers (monomethylation at Lys4 of H3, H3K4me1, SupplementaryFig. S4C and D). We found that both marks were enriched at both en-
hancers and at the TSS in comparison to a control region. Upon Hnf4a
knockdown both marks were significantly reduced in those regions
(Fig. 6G, Supplementary Fig. S4D). Since both Grhl3 and Hnf4α were
found also at the promoter (Figs. 3A and 6C, Supplementary Fig. S4C),
we investigated whether unidentified non-canonical binding sites are
present at the promoter. Neither Grhl3 nor Hnf4α were increasing
Cdh1 promoter-only reporter gene activity, indicating that both factors
are only indirectly linked to the TSS (Supplementary Fig. S4E). Taken to-
gether, our results suggest that Hnf4α is crucial for stabilizing the chro-
matin structure in a permissive state, enabling proper binding of Grhl3
to the intronic enhancers for a robust upregulation of E-cad expression.
3.6. Grhl3 contributes to the regulation of Hnf4α expression during MET
To analyze how Grhl3 and Hnf4α are connected to orchestrate the
re-expression of E-cad during MET, we studied E-cad, Grhl3 and
Hnf4α mRNA levels in a time course experiment after the withdrawal
of TGFβ3 (Fig. 7A). We noticed that the expression of Grhl3 was re-
stored rapidly and was first to reach 50% of its initial level within 24 h.
While Hnf4α expression was also increasing, it fell behind the levels
of Grhl3 and reached 50% of the initial level 6–12 h later. E-cad expression
levels increased steadily butwere reaching original levels later thanGrhl3
andHnf4α after 72 h (Fig. 7A). Based on these data, we hypothesized that
besides its crucial role in the re-expression of E-cad, Grhl3 may also be
responsible for the upregulation of Hnf4αwhich in turn assists Grhl3 at
Cdh1 enhancers for appropriate re-establishment of E-cad levels.
The pattern of Hnf4α expression suggested a level of regulation by
Grhl3.We analyzed the expression of Hnf4α following the downregula-
tion of Grhl3. Our results confirmed that in response to the depletion
of Grhl3, a significant decrease in Hnf4α mRNA levels was observed
(Fig. 7B). Hnf4a is activated from two alternative promoters (P1 and
P2 in Fig. 7C) resulting in at least six different splice variants [34] with
themajor isoforms Hnf4α1 containing Exon 1A and Hnf4α7 containing
Exon 1D derived from the P1 and P2 promoters, respectively [35,36].
We found a Grhl3 recognition motif in P1 at−339 bp and a very well-
conserved one in P2 at −29 kb (Fig. 7C). Anti-Grhl3 ChIP revealed
that Grhl3was significantly enriched at P2 but not at P1 in cells recover-
ing from TGFβ3, similar to the enrichment at the Cdh1 enhancers
(Fig. 7D). This indicated that isoforms containing Exon 1D are regulated
by Grhl3, which is in agreement with previous findings showing that P2
is the active promoter in NMuMG cells controlling mainly Hnf4α8
expression [37]. In summary our results suggest that in response to
MET signals Grhl3 and Hnf4α are immediately upregulated, recruited
together with p300 to the Cdh1 locus and cooperatively initiate E-cad
expression. In parallel Grhl3 is directly activating Hnf4awhich acceler-
ates the MET program.
3.7. Grhl3 and Cdh1 expression is correlated in mouse mammary cells and
in human breast cancer cell lines
Finally, we aimed to evaluate whether our findings are also reflected
in expression data sets inmousemammary tissue and have implications
during tumor progression in human breast cancer samples. We first in-
vestigated whether Grhl1–3, Hnf4a and Cdh1 gene expression values
were correlated across normal mouse mammary tissue subpopulations
(i.e., stroma, basal, luminal, epithelial and total) using data from
GSE40877. We found that Grhl1, Grhl2, Grhl3 and Cdh1 were all highly
and positively correlated with each other (Fig. S5A; Supplementary
Table S8). Next, we analyzed data sets of established human breast can-
cer cell lines from the CCLE (Cancer Cell Line Encyclopedia) A significant
positive correlation among GRHL1–3 and CDH1was observed (Fig. S5B;
Supplementary Table S8). Microarray data sets of a fibroblast/breast
cancer cell co-culture system (GSE41678) revealed that the CDH1 ex-
pressing Cal51 breast cancer cell line highly expressed GRHL3 and/or
HNF4A in monoculture and in co-culture with fibroblasts (Fig. S5C). In
Fig. 6.Hnf4α facilitates the Grhl3 function. (A) Luciferase reporter assays in untreated NMuMG comparing the effect of Hnf4α on Grhl3 activation of Cl.3. (B) Luciferase reporter assays of un-
treated NMuMG cells showing the effect of Hnf4α depletion on Grhl3 activation of Cl.3. (C) ChIP of Grhl3 during MET upon the siRNA mediated downregulation of Hnf4α (Supplementary
Table S5); TSS, transcriptional start site. (D) qPCRanalysis of E-cadmRNA levels inNMuMGcells uponHnf4αdepletionduring the recovery fromTGFβ3 treatment. (E) Co-immunoprecipitation
(IP) of HA-Hnf4α and flag-Grhl3 in transiently transfected HEK-293 cells showing interaction of both factors using anti-HA affinity matrix (left) and anti-Grhl3 (right) antibodies coupled to
magnet beads. Immuno- and co-immunoprecipitated proteins (solid arrows) are distinguished from immunoglobulin heavy and light chains (open arrows). Bands corresponding toHA-Hnf4α
derived from previous anti-HA incubation are labeled in the lower blots (asterisks). (F and G) Hnf4α is required for proper histone acetylation at the intronic enhancers. ChIP analysis of p300
(F) and H3K9Ac (G) enrichment in response to Hnf4α depletion during the recovery from TGFβ3 treatment (Supplementary Table S5).
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Fig. 7. Grhl3 contributes to the regulation of Hnf4α expression. (A) qPCR analysis of mRNA levels of Grhl3, Hnf4α and E-cad in response to TGFβ3 treatment and withdrawal at the indi-
cated time-points. Green asterisks represent the p-values of comparing Grhl3 expression to that of Hnf4α and E-cad and the red ones represent the p-value of Hnf4α expression relative to
E-cad. See also Supplementary Table S7. (B) qPCR analysis of Hnf4αmRNA levels uponGrhl3 knockdown by siRNAs. (C)Hnf4a gene structurewith exons (boxes and vertical lines), show-
ing the relative location of the two promoters (depictedwith cornered arrows) and the sequence of the two Grhl3 motifs located within (top). The alignment shows the conserved Grhl3
binding site (highlighted) within the Hnf4a promoter P2. (D) ChIP analysis of Grhl3 enrichment on the Hnf4a promoters P1 and P2 in NMuMG cells in response to TGFβ3 treatment.
(E) Proposed model of Grhl3 and Hnf4αmediated looping and activation of the Cdh1 locus during MET. During EMT activators of E-cad expression are downregulated and transcription
at theCdh1 locus is blockedby at least one of the EMT inducers Zeb1, Zeb2, Snail, Slug and Twist by binding to E-boxes at thepromoter. Upon TGFβ3withdrawal andMET inductionGrhl3 is
binding to sites at Cdh1 and Hnf4a. Subsequent expression of Hnf4α leads to recruitment of Grhl3 and Hnf4α to intronic enhancers that induces DNA looping by interaction of the two
factors and interaction at the TSS that involves PolII (gray) and p300 (yellow) (enhancer cooperativity). The assembly and stabilization of the core transcriptionmachinery leads to induc-
tion of E-cad expression. Up- and downregulation is indicated by vertical green and red arrows, respectively.
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genes at low levels regardless of the culturingmethodology (Supplemen-
tary Fig. S5C).GRHL3 expressionwas correlatedwithGRHL1,GRHL2,CDH1
aswell aswithHNF4A (Fig. S5C; Supplementary Table S8). In linewith our
previous findings, these data support that Cdh1 expression is mainlydependent on Grhl3, whereas Hnf4α might contribute to the control of
the Cdh1 locus in a tissue and context-dependentmanner, especially dur-
ing EMT/MET processes. In contrast toMET in NMuMG cells, based on the
correlated expression in the analyzed data sets also Grhl1 and Grhl2
might be involved in Cdh1 locus control in steady-state conditions aswell.
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In early embryonic development proper cell adhesion mediated by
E-cad is crucial for the shaping of the embryo proper and for establish-
ing the embryonic–maternal interface of the placenta [38–41]. During
these processes EMT and MET programs are initiated and marked by
the switching of cadherin gene expression, suggesting that a tight and
dynamic control of the Cdh1 locus is mandatory. Proper promoter func-
tion is dependent on cis-regulatory elements located in the 47 kb intron
2.
By comparing sequences of the mammalian species mouse, man,
rhesus monkey, dog and horse followed by functional analyses, we
identified novel Cdh1 enhancers at +7.8 kb and+11.5 kb downstream
of the TSS. These enhancers are important for Cdh1 gene activation
during MET in NMuMG cells. Our data indicate that Grhl3 and Hnf4α
are mediating this activation by binding to the enhancers at +7.8 kb
and +11.5 kb, respectively. Abolishing the binding site for Grhl3 at
+7.8 kb resulted in loss of expression of a lacZ-reporter construct in
transgenic mouse embryos suggesting that this site plays a crucial role
for E-cad expression in vivo as well. Moreover, Grhl3 and Hnf4α were
bound to each other and cooperated during gene activation. In addition
to their own binding sites they were also found to occupy each other's
enhancers. Despite of the lack of binding siteswithin the E-cad promoter,
theywere also detected at the TSS, suggesting looping of DNA to complex
all involved transcription factors with the basal transcription machinery
(Fig. 7E).
The family of grainyhead transcription factors has been first described
inDrosophila. Later threehomologs of a family of sixmemberswere iden-
tified in vertebrates: grainyhead-like 1 (Grhl1), Grhl2 and Grhl3 [42–44].
In Drosophila, grainyhead (grh) is driving postembryonic neuroblast
function and proliferation in part by affecting DE-cadherin expres-
sion [28,44]. In mammals, the expression is largely confined to epi-
thelia. Although their expression only partially overlaps, overall at
least one member is coexpressed with E-cad [19,42,43]. Knockout
mice were described for all three, with Grhl2 showing the most se-
vere phenotype as embryos die at E11.5 [27,29,30,45]. Each knockout
show common defects in neural tube closure at specific sites, establish-
ment of epithelial function, differentiation and barrier formation, all of
which depend on proper E-cad function. Similarly, Hnf4α, an orphan
member of the nuclear receptor superfamily, is also coexpressed with
E-cad in several tissues such as liver, intestine and kidney [19,46]. Zygotic
depletion of Hnf4α results in a pregastrulation defect due to its role in
the visceral endoderm [47]. Conditional ablation of Hnf4α in the embry-
onic liver primordium or in the colon displays defects in epithelial spec-
ification and in organ function and homeostasis [31,48]. Cdh1 was one
prominent gene that was significantly reduced upon Hnf4α depletion
in the liver, suggesting a generalmechanism of Cdh1 transcriptional con-
trol by Hnf4α in epithelia. Their role in epithelial specification, an over-
lapping expression with E-cad and the phenotypes of knockout mice,
renders Grhl factors and Hnf4α prime candidates for the regulation
of Cdh1.
Are Grhl factors redundant for E-cad regulation? It was recently
shown by Werth and colleagues that Grhl2 acts similarly to grh in
Drosophila development in regulating Cdh1 transcription [21,28]. Loss
of Grhl2 reduces E-cad expression in several epithelia including the
gut tube and the otic vesicle. In mouse inner medullary collecting duct
cells (mIMCD-3) and embryonic lungs Grhl2 binds to the same enhanc-
er at 7.8a + b that was occupied by Grhl3 in our experiments [21,28].
Interestingly, Grhl2 did not show an activating effect in our system
(Fig. 2B, Supplementary Fig. S3D). Only Grhl3 was able to upregulate
the luciferase reporter and Grhl3 depletion during MET abolished the
re-expression of E-cad and the re-establishment of an epithelial state
(Fig. 4, Supplementary Fig. S3D). Although Grhl3 is highly expressed
in the skin and mammary bud epithelium [19,42,43], a comprehensive
expression analysis inmammary gland epithelium is lacking. Microarray
re-analysis revealed that Grhl1–3 are correlated with Cdh1, and thus areenriched in epithelial/luminal cell populations in mouse mammary
tissues.We here used NMuMG cells mainly as a simplemodel for revers-
ible EMT andMET to study Cdh1 control using TGFβ as one of many trig-
gers to induce EMT. Hence, although we obtained strong support of a
cooperativitymechanism of the two transcription factors in Cdh1 regula-
tion, generalization is limited. However, also in epithelia during embry-
onic development and independent of MET the Grhl3-binding site is
crucial for proper Cdh1 gene activation. Since this site would potentially
be bound by other factors, we cannot completely rule out that in
mouse embryos our transgenic reporter construct is regulated also by
other Grhl familymembers, conferring reduced Cdh1 reporter gene activ-
ity independent of Grhl3. However, expression analysis showed that
Grhl3 and Grhl1 rather than Grhl2 are expressed at high levels in the
stomach epithelium [29,42]. Additionally, we did not observe Cdh1
transactivation by Grhl2 in NMuMG and other cell lines, indicating
tissue-specificity of individual Grhl factors. It will be interesting to ana-
lyze whether Grhl2 in mIMCD-3 cells is interacting in a similar fashion
with Hnf4α or different regulators of Cdh1 as does Grhl3.
A general regulation of Cdh1 by Grhl3 and Hnf4α independent of
MET is very likely. First, loss of Hnf4α in the liver or the intestinal
epithelium of the colon substantially reduced E-cad expression due to
direct interaction of Hnf4α with a site upstream of the TSS [31,48].
Second, the siRNA mediated removal of Grhl3 resulted in 30% decrease
in E-cad mRNA levels also in a variety of epithelial cell lines including
untreated NMuMG, CMT, CSG, P19, ESCs and keratinocytes (Supple-
mentary Fig. S3C). Lastly, reporter gene activity in the endoderm of
transgenic embryos was depending on the Grhl3 recognition motif.
This indicates that Grhl3 is regulating E-cad levels not only during
MET events.
Previous data suggested that the complexity of Cdh1 gene regulation
is governed by interplay of multiple cis-regulatory elements dispersed
throughout the locus. We now provide evidence to how this mode of
transcriptional control is achieved in molecular terms by the coopera-
tion of two distal enhancers separated by 4 kb. Recently, a novel type
of super-enhancers has been identified in embryonic stem cells. They
represent clusters of normal enhancers defined by continuous several
kb long stretches occupied by core transcription factors of pluripotency
[49]. The presence of super-enhancers at Cdh1 intron 2 cannot be
excluded, but the detection of distinct DNaseI hypersensitive sites at
each conserved cluster supports the presence of individual small en-
hancers (not shown). Long-range interaction of distant cis-regulatory
elements and DNA looping is a general mechanism to control expres-
sion [50]. Binding to the pre-assembled transcriptional machinery is
then activated by factors bound to thedistal enhancers for efficient tran-
scription [51]. Enhancer cooperativity was shown for other loci, e.g. the
β-globin locus [52] and theMMP13 locus by LEF1 [53]. Using 3C analysis
Vakoc et al. showed that GATA-1 and FOG-1 are required to establish the
physical interaction of the locus control region and the β-major globin
promoter [52]. Enhancer cooperativity during MET may reflect the
need for immediate E-cad upregulation to efficiently enter an epithelial
state. This enhancer cooperativity which utilizes Grhl3 and Hnf4α may
also affect other epithelial genes. The detected correlation between the
expression of CDH1, GRHL3 and HNF4A in many cancer cell lines, breast
cancer specimens as well as lung cancer (Supplementary Fig. S5 and
data not shown), suggests a general mode of regulation. It is tempting
to speculate that we identified a general mechanism that is also acting
on Cdh1 in circulating tumor cells once they activate MET and start
colonization during metastasis formation.
In summary, we identified how Grhl3 is orchestrating E-cad expres-
sion during MET. External stimuli like TGFβ induce EMT leading to
Hnf4α and Grhl3 downregulation and activation of transcription factors
of the ZEB (Zeb1, Zeb2), Snail (Snail, Slug) and bHLH (Twist) families
which results in shutdown of E-cad transcription. Upon reversion of
the process e.g. by withdrawal of TGFβ EMT transcription factors are
downregulated and Grhl3 expression is initiated. To facilitate MET
Grhl3 acts on both Hnf4a and Cdh1 transcriptional activation by binding
741H. Alotaibi et al. / Biochimica et Biophysica Acta 1849 (2015) 731–742to the corresponding binding sites. To fully activate E-cad expression,
Hnf4α is recruited to the binding site at 11.5 of the Cdh1 locus. Here, it
forms a complex with Grhl3, p300 and probably with other proteins
to connect proximal and distal cis-regulatory elements by induction of
a DNA loop. This facilitates the assembly of a functional transcription
machinery complex at the promoter. Hnf4α and Grhl3 cooperatively
bind to their cognate binding sites supporting each other's recruitment.
Once the MET process is completed, Grhl3 is released from the Hnf4a
promoter and also partially from the Cdh1 promoter at site 7.8b and
steady-state E-cad expression requires only Hnf4α (Fig. 7E).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbagrm.2015.01.005.
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